{
    "id": 1799,
    "fullName": "BRCA2 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 loss indicates loss of the BRCA2 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "loss",
    "createDate": "09/18/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5535,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3881,
                "therapyName": "Etoposide + YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5529,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 demonstrated increased cytotoxicity compared to control in BRCA2-deficient ovarian adenocarcinoma cell lines in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3880,
                "therapyName": "YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 3713,
                "name": "ovary adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10020,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line deficient for BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5537,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3883,
                "therapyName": "Olaparib + YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14518,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APTO-253 treatment resulted in decreased viability in BRCA2-deficient ovarian cancer cells in culture (PMID: 29626126).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3519,
                "therapyName": "APTO-253",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11722,
                    "pubMedId": 29626126,
                    "title": "APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29626126"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5530,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3880,
                "therapyName": "YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12850,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NMS-P118 enhanced the effects of Temodar (temozolomide) in BRCA2-deficient pancreatic cancer xenograft models, demonstrating inhibition of tumor growth and a complete response in 50% (3/6) of the models (PMID: 26222319).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 6683,
                "therapyName": "NMS-P118 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6203,
                    "pubMedId": 26222319,
                    "title": "Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26222319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5536,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 3882,
                "therapyName": "Radiotherapy + YU238259",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5087,
                    "pubMedId": 26116172,
                    "title": "YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3284,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3921,
                    "pubMedId": 26510020,
                    "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26510020"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19066,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an acinar cell carcinoma patient harboring BRCA2 T2766Nfs*10 and loss of the wild-type allele with disease recurrence and liver metastasis demonstrated complete remission following treatment with Platinol (cisplatin) and TS-1 (tegafur-gimeracil-oteracil potassium) (PMID: 25743105).",
            "molecularProfile": {
                "id": 33959,
                "profileName": "BRCA2 T2766Nfs*10 BRCA2 loss"
            },
            "therapy": {
                "id": 8903,
                "therapyName": "Cisplatin + TS-1",
                "synonyms": null
            },
            "indication": {
                "id": 3025,
                "name": "acinar cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14156,
                    "pubMedId": 25743105,
                    "title": "Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25743105"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1788,
            "profileName": "BRCA2 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 3452,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "BRCA2 loss"
                },
                {
                    "id": 3453,
                    "name": "PARP-1 Inhibitor",
                    "profileName": "BRCA2 loss"
                }
            ]
        },
        {
            "id": 33959,
            "profileName": "BRCA2 T2766Nfs*10 BRCA2 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}